Approach to non-type 2 asthma

•There is no globally accepted definition of non-T2 asthma which has been identified in studies by absence of T2-high markers. •Pathophysiology of neutrophilic asthma is poorly understood with possible role of type-1 and type-17 helper cells. •Cytokines including interleukin (IL)-17, IL-6, IL-8, IL-1β, tumor necrosis factor and interferon gamma may also play a role. •Azithromycin and Tezepelumab are the currently available therapies for patients with non-T2 asthma. •Imatinib and clazakizumab are being actively studied for this indication.